cCAM Biotherapeutics develops novel immunotherapies for cancer. cCAM’s lead agent, CM-24, is an immunomodulatory antibody that blocks a novel immune checkpoint, thereby harnessing  the patient’s immune system to attack tumors. In July 2015, the company was acquired by Merck.

biopharmaceuticals
Acquired by Merck
Visit Website
Additional Portfolio Companies
ABAC Therapeutics
Adicet Bio
ArQule
Cathworks
Dynacure
cCAM Biotherapeutics
CheckCap
Eloxx Pharmaceuticals
Enlivex Therapeutics
Entera Bio
Eyevensys
EyeYon
ForSight Vision6 (“V6”)
Hairstetics
Horama
Keros Therapeutics
Kite Pharma
Levation Pharma
LogicBio Therapeutics
Metabomed
NovellusDX
Novus Therapeutics
Ocon Medical
Prevail Therapeutics
PACT Pharma
Pi Therapeutics
Protalix
Raziel Therapeutics
ReWalk
VBI Vaccines
Step Pharma
StimatixGI
Sweetch
TargEDys
UroGen
V-Wave
July 12, 2015